Also trades as: STX.L (LSE) · $vol 0M
SHIEF OTC
Shield Therapeutics plc
1W: +0.0%
1M: +21.6%
3M: +7.0%
YTD: -41.4%
1Y: -15.8%
3Y: -13.5%
5Y: -93.7%
$0.09
+0.00 (+0.00%)
Overview
Chart
Smart Money
Financials
Income Statement
Cash Flow
Balance Sheet
Earnings
Analysis
Technicals
Weather
Peers
ESG
Institutions
Dark Pool
Short Interest
Smart Money Score
No convergence signal
Key Statistics
Market Cap$91.6M
52W Range0.0521-0.1679
Volume16,237
Avg Volume30,504
Beta1.72
Dividend—
Analyst Ratings
No analyst coverage
Company Info
CEOAnders Lundstrom
Employees61
SectorHealthcare
IndustryDrug Manufacturers - Specialty & Generic
IPO Date2019-12-06
Websiteshieldtherapeutics.com
Northern Design Centre
Gateshead, GH NE8 3DF
GB
Gateshead, GH NE8 3DF
GB
44 1915 118 500
About Shield Therapeutics plc
Shield Therapeutics plc operates as a specialized pharmaceutical firm, dedicated to developing and bringing to market advanced clinical therapies that address significant unfulfilled medical requirements. Its flagship product, Accrufer/Feraccru, offers an innovative, non-salt-based oral treatment specifically for adults suffering from iron deficiency, irrespective of whether anemia is present. Furthermore, the company is advancing PT20, a pioneering iron-based phosphate binder that has successfully concluded its pivotal Phase II trials for managing hyperphosphatemia in individuals with chronic kidney disease. This enterprise was founded in 2008 and maintains its headquarters in Gateshead, United Kingdom.
Recent Insider Trades
No insider trades found